KJIM

Supplementary Table 5. Univariable and multivariable logistic model for adverse skin reactions

Characteristic	Without adverse skin reactions (n = 9,984)	With adverse skin reactions (n = 233)	OR (95% CI)	aOR (95% CI)
Sex, female	5,557 (55.7)	137 (58.8)		
Age	31.53 ± 23.29	34.94 ± 23.23	1.14 (0.87–1.48)	
≤ 5	1,843 (18.5)	40 (17.2)	1.00	1.00
6–18	2,272 (22.8)	32 (13.7)	0.65 (0.41–1.04)	0.70 (0.44–1.13)
19–35	1,303 (13.1)	45 (19.3)	1.56 (1.01–2.40)	1.69 (1.08–2.65)
36–65	4,093 (41.0)	98 (42.1)	1.10 (0.76–1.60)	1.12 (0.76–1.64)
66–75	355 (3.6)	14 (6.0)	1.82 (0.98–3.38)	1.70 (0.91–3.17)
≥ 76	118 (1.2)	5 (2.1)	1.95 (0.76–5.04)	1.68 (0.64–4.40)
LTBI regimen				
6–9H	3,699 (37.0)	83 (35.6)	1.00	
3HR	5,396 (54.0)	132 (56.7)	1.09 (0.83–1.44)	
4R	889 (8.9)	18 (7.7)	0.90 (0.54–1.51)	
Comorbidities				
Chronic pulmonary disease	2,890 (28.9)	83 (35.6)	1.36 (1.04–1.78)	1.24 (0.93–1.66)
Diabetes mellitus	871 (8.7)	16 (6.9)	0.77 (0.46–1.29)	
Renal failure	50 (0.5)	1 (0.4)	0.86 (0.12–6.23)	
Liver disease	402 (4.0)	15 (6.4)	1.64 (0.96–2.79)	
AIDS	4 (0.0)	0 (0.0)	< 0.001 (0–∞)	
Malignancy	279 (2.8)	8 (3.4)	1.24 (0.61–2.53)	
Rheumatic disease/ collagen–vascular disease	174 (1.7)	12 (5.2)	3.06 (1.68–5.58)	2.37 (1.29–4.38)
Alcohol abuse	64 (0.6)	0 (0.0)	< 0.001 (0–∞)	
Steroid use	3,837 (38.4)	128 (54.9)	1.95 (1.50–2.54)	1.79 (1.37–2.34)

Values are presented as number (%) or mean ± standard deviation.

OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; LTBI, latent tuberculosis infection; 6–9H, six to nine months of isoniazid; 3HR, three months of isoniazid/rifampin; 4R, four months of rifampicin; AIDS, acquired immune deficiency syndrome.